Therapeutic Asset Ratings
423 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Amg 305
Cancer
Amgen
P1
C
(39)
asc61
Cancer
Ascletis Pharmaceuticals Co., Ltd.
P1
C
(39)
bat6026
Cancer
Bio-Thera Solutions
P1
C
(39)
bat8006 for
Cancer
Bio-Thera Solutions
P1
C
(39)
bay2416964
Cancer
Bayer
P1
C
(39)
bay2862789
Cancer
Bayer
P1
C
(39)
BMS-986360
Cancer
Bristol-Myers Squibb
P1
C
(39)
BMS-986416
Cancer
Bristol-Myers Squibb
P1
C
(39)
KN510
Cancer
New Cancer Cure-Bio Co.,Ltd.
P1
C
(39)
KN713
Cancer
New Cancer Cure-Bio Co.,Ltd.
P1
C
(39)
kt-253
Cancer
Kymera Therapeutics, Inc.
P1
C
(39)
Lartesertib
Cancer
EMD Serono Research & Development Institute, Inc.
P1
C
(39)
Migoprotafib
Cancer
Genentech, Inc.
P1
C
(39)
ntq1062
Cancer
Nanjing Chia-tai Tianqing Pharmaceutical
P1
C
(39)
Olomorasib
Cancer
Eli Lilly and Company
P1
C
(39)
ro7623066
Cancer
Hoffmann-La Roche
P1
C
(39)
Shr-7631
Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
P1
C
(39)
yh004
Cancer
Eucure (Beijing) Biopharma Co., Ltd
P1
C
(39)
Zggs15
Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
P1
C
(39)
BMS-986345
Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P1/2
C
(39)
Abbv-400
Cancer
AbbVie
P1
C
(36)
Abbv-706
Cancer
AbbVie
P1
C
(36)
Abx-001
Cancer
Abalos Therapeutics GmbH
P1
C
(36)
acr246 for
Cancer
Hangzhou Adcoris Biopharmacy Co., Ltd
P1
C
(36)
ak146d1 for
Cancer
Akeso
P1
C
(36)
Showing 201 to 225 of 423 assets
Previous
Page 9 of 17
Next
